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Multivalent vaccines are designed to immunize against two or more pathogens in a single
dose vaccination. A challenge for wide spread use of these vaccines is their lower protec-
tion efficacy compared to monovalent vaccines that immunize individuals against a single
pathogen. We sought, for the first time, to evaluate the outcomes of bivalent and mono-
valent vaccines in terms of the reduction in the number of infections over time. For this
evaluation, we developed epidemiological models governing the transmission dynamics of
two immunologically unrelated pathogens, where immunity conferred by vaccination or
natural infection of one pathogen does not provide any cross-protection against the other
pathogen. We assumed that a monovalent vaccine provides full, but temporary, protec-
tion against a particular pathogen. While protecting against both pathogens requires
two pathogen-specific monovalent vaccines, a single dose of the bivalent vaccine provides
partial protection against both pathogens. We analyzed the two models to investigate
the impact of vaccination. In addition to examining global behaviours and disease per-
sistence of the models, we performed simulations to show the existence of a biologically
feasible region for the bivalent vaccine to outperform monovalent vaccines for prevention
of disease transmission using a lower number of vaccines.
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1. Introduction
Vaccination has proven as the most effective and economical measure against many
communicable diseases.1–3 The aim of vaccination is to provide active acquired
immunity against a particular pathogen, thereby preventing infection and related
outcomes upon exposure to the pathogen. Since the discovery of the polysaccharide
conjugate vaccines in the late 1980s,4 the impact of vaccination on the pathogen-
population landscape has dramatically changed. Haemophilus influenzae serotype
b (Hib) is the first infection against which a polysaccharide conjugate vaccine was
developed and implemented as part of the infant immunization programs in several
affected populations.4 Since then, a number of multivalent combined or unimolecular
vaccines have been produced to protect individuals against different pathogens or
different serotypes of a pathogen using a single vaccine dose.5–7 A particular example
is the DTaP-IPV-Hib combined vaccine that protects individuals against diphtheria,
tetanus, pertussis, polio and Hib.8
Multivalent vaccines have the advantage of providing protection against two
or more diseases in a single dose, and therefore eliminate a number of logistical
and administrative challenges associated with vaccination using monovalent vac-
cines. However, the protection efficacy of multivalent vaccines may be lower than
that provided by individual monovalent vaccines. For instance, several studies have
demonstrated lower immunogenicity to the Hib component of the DTaP-IPV-Hib
combined vaccine products that include Hib antigens when compared with indi-
vidually administered Hib polysaccharide conjugate vaccine.9–12 In addition to the
lower protection efficacy conferred by such multivalent vaccines, waning immunity
and deferral of boosting may be a cause for the resurgence of some severe infections,
such as invasive Hib disease.13
In this study, we develop vaccination models to investigate, the effect of
monovalent and bivalent vaccines, and compare the outcomes in terms of the
vaccine-induced protection and vaccine coverage. We consider these models for two
pathogens (referred to as pathogen A and pathogen B), and assume that no cross-
protection is conferred through vaccination or natural infection. In the monovalent
model, vaccines are assumed to provide full protection against each pathogen for a
certain period of time. In the bivalent model, we assume that the vaccine is imper-
fect, providing only partial protection against each pathogen. While investigating
theoretical aspects of these models, we simulate them to illustrate the time profiles
of infection spread in the population. By means of simulations, we also show the
importance of the durations of vaccine-induced protection and naturally acquired
immunity when comparing the outcomes of these models.
2. Vaccination models
To develop vaccination models, we divide a homogeneously mixing population of
size N into classes of susceptibles (S), infected individuals with pathogen A (I
A
),
infected individuals with pathogen B (I
B
), recovered individuals from infection with
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pathogen A (T
A
), recovered individuals from infection with pathogen B (T
B
), in-
fected individuals with pathogen B after recovery from infection with pathogen
A (J
B
), infected individuals with pathogen A after recovery from infection with
pathogen B (J
A
), and recovered individuals after subsequent infections with both
pathogens (R). We assume that recovery from infection with one pathogen does not
provide any cross-protection against the other pathogen. We exclude the occurrence
of co-infection with both pathogens A and B from our models. Vaccination models
include other subpopulations based on the type of vaccine being implemented. In
the absence of vaccination, the model (2.3) is expressed as the following system of
differential equations
S′ = Λ− (F
A
+ F
B
)S − dS + θ(T
A
+ T
B
+R),
I ′
A
= F
A
S − γ
A
I
A
− dI
A
,
I ′
B
= F
B
S − γ
B
I
B
− dI
B
,
T ′
A
= γ
A
I
A
− F
B
T
A
− dT
A
− θT
A
,
T ′
B
= γ
B
I
B
− F
A
T
B
− dT
B
− θT
B
,
J ′
A
= F
A
T
B
− γ
A
J
A
− dJ
A
,
J ′
B
= F
B
T
A
− γ
B
J
B
− dJ
B
,
R′ = γ
A
J
A
+ γ
B
J
B
− dR− θR,
(2.1)
where
F
A
= β
A
I
A
+ J
A
N
, F
B
= β
B
I
B
+ J
B
N
.
Parameters of this system are described in Table 2.1. This system will be used
as a basic framework for the development of monovalent and bivalent vaccination
models.
2.1. The monovalent vaccine model (MVM)
In this model, susceptible individuals may be vaccinated against pathogen A (W
A
)
only, pathogen (W
B
) only, or both pathogen (W
AB
). Vaccination against each
pathogen is assumed to provide full protection for a certain period of time. Af-
ter the vaccine-induced protection has waned, individuals will become susceptible
to the infection again. We assume that the durations of vaccine-induced protec-
tion and naturally acquired immunity (through natural infection) are the same for
both pathogens A and B. Considering the basic framework in (2.1), the MVM is
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expressed by
S′ = (1− pm)Λ− (FA + FB )S − dS + θ(TA + TB +WA +WB +WAB +R),
I ′
A
= F
A
S − γ
A
I
A
− dI
A
,
I ′
B
= F
B
S − γ
B
I
B
− dI
B
,
T ′
A
= γ
A
I
A
− F
B
T
A
− dT
A
− θT
A
,
T ′
B
= γ
B
I
B
− F
A
T
B
− dT
B
− θT
B
,
J ′
A
= F
A
T
B
− γ
A
J
A
− dJ
A
,
J ′
B
= F
B
T
A
− γ
B
J
B
− dJ
B
,
W ′
A
= pmrAΛ− FBWA − dWA − θWA ,
W ′
B
= pmrBΛ− FAWB − dWB − θWB ,
X ′
A
= F
A
W
B
− γ
A
X
A
− dX
A
,
X ′
B
= F
B
W
A
− γ
B
X
B
− dX
B
,
W ′
AB
= pmrABΛ− dWAB − θWAB ,
R′ = γ
A
J
A
+ γ
B
J
B
+ γ
A
X
A
+ γ
B
X
B
− dR− θR,
(2.3)
where
F
A
= β
A
I
A
+ J
A
+X
A
N
, F
B
= β
B
I
B
+ J
B
+X
B
N
.
In this model, X
A
represents the class of individuals who are infected with pathogen
A after being vaccinated only against pathogen B. Similarly, X
B
represents the class
of individuals who are infected with pathogen B after being vaccinated only against
pathogen A. The overall vaccination coverage is given by pm (where 0 ≤ pm ≤ 1).
The parameters r
A
, r
B
, and r
AB
represent respectively the fractions of this coverage
considered for vaccination against pathogen A, against pathogen B, and against
both pathogens, giving r
A
+ r
B
+ r
AB
= 1. Other parameters of this model are
described in Table 2.1.
2.2. The bivalent vaccination model (BVM)
In this model, we assume that a single dose of the vaccine provides protection
against both pathogens A and B. In contract to the monovalent vaccine, we assume
that the bivalent vaccine confers only partial protection against each pathogen,
which reduces susceptibility to infection. Therefore, vaccinated individuals (V
AB
)
may encounter infection with pathogen A or pathogen B at reduced transmission
rates. Recovered individuals from infection with pathogen A (Q
A
) and pathogen
B (Q
B
) following vaccination may respectively acquire infection with pathogen B
(Y
B
) and pathogen A (Y
A
). Inclusion of these subpopulations to the basic framework
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Table 1. Description of parameters and their values (ranges) used in simulations of the monovalent
and bivalent vaccination models.
Model parameters Description Values/Range
Λ recruitment rate 10 yr−1
d natural death rate 1/70 yr−1
βA , βB transmission rates 0.12, 0.13 yr
−1people−1
γA , γB recovery rates from infection 1/10 days
−1
θ rate of waning immunity varied
pm vaccination coverage varied: [0, 1]
rA fraction vaccinated against pathogen A only 0.2
rB fraction vaccinated against pathogen B only 0.2
rAB fraction vaccinated against both pathogens 1− (rA + rB )
pm(rA + rAB ) vaccination coverage against pathogen A varied
pm(rB + rAB ) vaccination coverage against pathogen B varied
pb vaccination coverage varied: [0, 1]
κA , κB transmission reduction factors due to vaccine 0.2
gives the following system of differential equations:
S′ = (1− pb)Λ− (FA + FB )S − dS + θ(TA + TB +QA +QB +R+ VAB ),
I ′
A
= F
A
S − γ
A
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− dI
A
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I ′
B
= F
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B
− dI
B
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T ′
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A
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A
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A
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A
,
T ′
B
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B
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A
T
B
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B
− θT
B
,
J ′
A
= F
A
T
B
− γ
A
J
A
− dJ
A
,
J ′
B
= F
B
T
A
− γ
B
J
B
− dJ
B
,
V ′
AB
= pbΛ− (κAFA + κBFB )VAB − dVAB − θVAB ,
X ′
A
= (κ
A
F
A
)V
AB
− γ
A
X
A
− dX
A
,
X ′
B
= (κ
B
F
B
)V
AB
− γ
B
X
B
− dX
B
,
Q′
A
= γ
A
X
A
− (κ
B
F
B
)Q
A
− dQ
A
− θQ
A
,
Q′
B
= γ
B
X
B
− (κ
A
F
A
)Q
B
− dQ
B
− θQ
B
,
Y ′
A
= (κ
A
F
A
)Q
B
− γ
A
Y
A
− dY
A
,
Y ′
B
= (κ
B
F
B
)Q
A
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B
Y
B
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,
R′ = γ
A
J
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B
J
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A
Y
A
+ γ
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(2.5)
where
F
A
= β
A
I
A
+ J
A
+X
A
+ Y
A
N
, F
B
= β
B
I
B
+ J
B
+X
B
+ Y
B
N
.
In this model, pb represents the vaccination coverage with 0 ≤ pb ≤ 1. Other
parameters are described in Table 2.1.
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3. Analysis of the MVM
The system is at an equilibrium if the time derivatives of its variables are zero. The
equation
N ′ = Λ− dN (3.1)
describes the dynamics of the total population. At the equilibrium for the total
population we have N∗ = Λ/d, which is globally attracting. From the system speci-
fications, it follows that nonnegative initial values give rise to nonnegative solutions.
It is thus meaningful to define the phase space Γ for model (2.3), as
Γ = {x = (S, I
A
, . . . , R) ∈ R13+ : N ≤ N∗}.
The space Γ is positively invariant with respect to the model (2.3). The solutions
are bounded, and remain nonnegative for nonnegative initial values. There is a
unique disease-free equilibrium (DFE) given by
S0 = (1− pm)Λ
d
+
pmΛθ
(d+ θ)d
,
I0
A
= 0, J0
A
= 0, X0
A
= 0, I0
B
= 0, J0
B
= 0, X0
B
= 0,
T 0
A
= 0, T 0
B
= 0, R0 = 0,
W 0
A
=
pm rAΛ
d+ θ
, W 0
B
=
pm rBΛ
d+ θ
, W 0
AB
=
(pm rAB )Λ
d+ θ
.
(3.3)
The disease-free subspace is defined as
Γ0 = {x ∈ Γ : IA = JA = XA = IB = JB = XB = 0}.
In Γ0, model (2.3) reduces to a linear system, and it is easy to obtain that the DFE
is globally asymptotically stable in the disease-free subspace Γ0.
We define the corresponding reproduction numbers for pathogens A and B in
model (2.3), as we introduce an individual infected with pathogen A or B, into a
completely susceptible population:
RAm = βA
(γ
A
+ d)N∗
(S0 +W 0
B
) =
β
A
(γ
A
+ d)
(
1− pm(1− rB )d
d+ θ
)
,
RBm = βB
(γ
B
+ d)N∗
(S0 +W 0
A
) =
β
B
(γ
B
+ d)
(
1− pm(1− rA)d
d+ θ
)
.
(3.5)
Theorem 3.1 The DFE of model (2.3) is locally asymptotically stable if
max{RAm, RBm} < 1, and unstable if max{RAm, RBm} > 1.
A Proof of the theorem is provided in Appendix A. We performed theoretical
analysis to investigate the local and global dynamics of the MVM. In particular,
after establishing the existence of a unique DFE and describing its local stability, the
existence of endemic equilibria are also investigated. Various threshold quantities–
reproduction numbers–are defined to describe local and global stability, and we give
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sufficient conditions for disease persistence in the MVM. These analyses provide rich
dynamics of the model, and we refer the reader to Appendix A for their derivations
and proofs.
4. Analysis of the BVM
The steady state N∗ = Λ/d for the total population is globally attracting in model
(2.5). Furthermore, nonnegative initial conditions give rise to nonnegative solutions.
The phase space for model (2.5) is defined as
Γ = {x = (S, I
A
, . . . , R) ∈ R15+ : N ≤ N∗},
where for simplicity we use the same notation as for model (2.3). The space Γ is
positively invariant with respect to model (2.5). The solutions are bounded, and
remain nonnegative for nonnegative initial values.
There is a unique DFE given by
S0 = (1− pb)N∗ + θpbN
∗
(d+ θ)
,
V 0
AB
=
dpbN
∗
d+ θ
,
I0
A
= 0, J0
A
= 0, X0
A
= 0, Y 0
A
= 0,
I0
B
= 0, J0
B
= 0, X0
B
= 0, Y 0
B
= 0,
T 0
A
= 0, T 0
B
= 0, Q0
A
= 0, Q0
B
= 0, R0 = 0.
(4.2)
In the disease-free subspace Γ0 = {x ∈ Γ : IA = JA = XA = YA = 0, IB = JB =
X
B
= Y
B
= 0} the DFE is globally asymptotically stable in model (2.5). We define
the reproduction numbers for pathogens A and B as:
RAb = βA
(γ
A
+ d)N∗
(S0 + κ
A
V 0
AB
) =
β
A
(γ
A
+ d)
(
1− pb(1− κA)d
d+ θ
)
,
RBb = βB
(γ
B
+ d)N∗
(S0 + κ
B
V 0
AB
) =
β
B
(γ
B
+ d)
(
1− pb(1− κB )d
d+ θ
)
.
(4.3)
Theorem 4.1 In model (2.5), the DFE is locally asymptotically stable if
max{RAb, RBb} < 1, and unstable if max{RAb, RBb} > 1.
The proof of this theorem is similar to Theorem 3.1, and we omit it. One can also
show the persistence of the disease, and investigate the local and global behaviour
of the BVM. Details of such dynamics are provided in Appendix B. Proofs and
detailed explanations are omitted where they are similar to those obtained for the
MVM.
5. Simulation results
The theoretical analyses of the MVM and BVM (see Appendices A and B) provide
rich dynamics of these systems with respect to their local and global behaviours.
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The purpose of our simulations here is to compare these models to determine the
conditions under which a bivalent vaccine could outcompete monovalent vaccines in
preventing infection spread by both pathogens. This comparison is associated with
two key parameters including the level of vaccine-induced protection and vaccination
coverage of individuals in the population. In the BVM, the number of vaccines is
the same as the vaccination coverage; however, in the MVM, protecting individuals
against both pathogens with the same coverage as in the BVM requires twice as
many vaccinations.
In the MVM, the number of individuals vaccinated per unit time is pmΛ. A
fraction r
A
+r
B
of vaccinated newborns receives vaccine against one pathogen only,
and the remaining fraction r
AB
receives vaccines against both pathogens A and B.
Since r
A
+ r
B
+ r
AB
= 1, the total number of vaccines administered per unit time is
(r
A
+ r
B
) pmΛ + 2 rAB pmΛ = pmΛ(1 + rAB ). In the BVM, the number of newborns
vaccinated per unit time is pbΛ, and each vaccinee receives a single dose of vaccine
against both pathogens. Hence, the total number of vaccines is pbΛ. It is therefore
meaningful to compare the total vaccine doses (1 + r
AB
) pmΛ and pbΛ per unit
time in the two models. We performed numerical simulations to reveal whether it
is possible to reduce the incidence of infections through a bivalent vaccine without
increasing the total number of vaccines in the population compared with the MVM.
Heatmaps presented in Figure 1 show the difference in the cumulative number of
infections for each pathogen in the two models over twenty years following the start
of vaccination. The simulations were run when pm and pb vary in their respective
ranges between 0 (in the absence of vaccination) and 1 (full vaccination coverage
of newborns). In our simulations, four values were considered for the average time
period of protection following vaccination or recovery from infection. Figure 1 shows
the results for lifetime protection, i.e., θ = 0 (A,E); θ−1 = 5 years (B,F); θ−1 = 10
years (C,G); and θ−1 = 15 years (D,H) protection. Other parameter values are
provided in Table 2.1. First and second rows in Figure 1 correspond to the difference
in the cumulative number of infections between the two models for pathogens A and
B, respectively, with the magnitude of difference indicated by colour bars. The red
line indicates the same cumulative number of infections in the two models. The
black dashed-line corresponds to the same number of vaccine doses in both models
(i.e., pb = (1 + rAB )pm). Colours corresponding to positive numbers above the red
line identify the areas in the heatmaps where the cumulative number of infections
in the MVM is higher than that in the BVM. Any point below the black dashed-line
corresponds to a lower vaccine doses in the BVM compared with the MVM (that is,
pb < pm(1 + rAB )). We observed that the red line is below the black dashed-line for
values of θ (inverse of the duration of protection) used for simulations, implying that
it is possible to reduce the cumulative number of infections for each pathogen by
implementing a bivalent vaccine while using a lower number of vaccines compared to
the MVM. However, as the length of the duration of protection following vaccination
or recovery from natural infection increases, the difference in the cumulative number
of infections between the two vaccination models decreases.
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Fig. 1. Comparison of the cumulative number of infections caused by each pathogen in the two
models over twenty years, with varying vaccine coverages. In figures A and E, the duration of
immunity is lifetime (θ = 0). In other figures, the duration of immunity is θ−1 = 5 years (B,F),
θ−1 = 10 years (C,G), and θ−1 = 15 years (D,H). Colour bars show the difference between the
cumulative number of infections in the MVM and BVM. Positive values indicate a lower number
of infections using a bivalent vaccine. The red line corresponds to scenarios where the difference
in the cumulative number of infections is zero. In the area below the black dashed-line, the total
number of vaccines in the BVM is lower than that in the MVM. Other parameter values are
provided in Table 2.1.
For comparison purposes, we also simulated the time profiles of infection caused
by each pathogen in the two models. For these simulations we fixed a pair of (pm, pb)
in the area between the red and black dashed lines in the heatmaps. Figures 2 and 3
show these time profiles, where red, blue, and green curves correspond to the classes
I
A
, J
A
, and X
A
in each model, and magenta curves in Figure 3 correspond to the
class Y
A
in the BVM. Parameter values are provided in Table 2.1 with pm = 0.6 and
pb = 0.8. These simulations show a similar qualitative behaviour of infection curves
when the difference in the cumulative number of infections between the two models
is small. However, for large differences (Figure 1C), the corresponding infection
curves render different long-term behaviour (Figures 2-C,G and 3-C,G).
Remark. For the simulations presented here, we assumed the same duration of
immune protection following vaccination and recovery from natural infection. How-
ever, for many diseases, natural infection may induce stronger and longer-lasting
immunity than vaccination. We therefore carried out further simulations with a
longer protection period for immunity induced by natural infection compared to
that conferred by vaccination. We observed (Figure 4) that the effect of naturally
acquired immunity transcends the effect of vaccine-induced immunity.
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Fig. 2. Time profiles of infections caused by each pathogen in the MVM (2.3), where the duration
of immunity is (A,E): lifetime (θ = 0); (B,F): 5 years (θ−1 = 5); (C,G): 10 years (θ−1 = 10); and
(D,H): 15 years (θ−1 = 15). Red, blue, and green curves correspond to the classes IA , JA , and
XA . Vaccination coverages are pm = 0.6 and pb = 0.8. Other parameter values are provided in
Table 2.1.
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Fig. 3. Time profiles of infections caused by each pathogen in the BVM (2.5), where the duration
of immunity is (A,E): lifetime (θ = 0); (B,F): 5 years (θ−1 = 5); (C,G): 10 years (θ−1 = 10); and
(D,H): 15 years (θ−1 = 15). Red, blue, green, and magenta curves correspond to the classes IA ,
JA , XA , and YA . Vaccination coverages are pm = 0.6 and pb = 0.8. Other parameter values are
provided in Table 2.1.
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Fig. 4. Time profiles of infections caused by each pathogen in the BVM (2.5), where the duration of
vaccine-induced immunity is (A,B,E,F): 5 years; (C,D,G,H): 10 years; and the duration of naturally
acquired immunity is (A,B,E,F): 10 years; (C,D,G,H): 15 years. Red, blue, green, and magenta
curves correspond to the classes IA , JA , XA , and YA . Vaccination coverages are pm = 0.6 and
pb = 0.8. Other parameter values are provided in Table 2.1.
Discussion
Bivalent vaccines have the advantage of providing immunity against two or more
pathogens in a single-dose vaccination. These vaccines can potentially reduce costs
associated with the administration of single-dose vaccines for different diseases, in
addition to providing the uniform vaccination coverage of each disease. However,
the protection efficacy of such vaccines may not be as good as that provided by
individually administered monovalent vaccines against different pathogens. A num-
ber of bivalent vaccines are currently being used in many countries,5–8 however an
important question is whether these vaccines could reduce the morbidity caused by
different pathogens in the population without increasing vaccine doses compared to
monovalent vaccines.
To address this question, we developed, for the first time, epidemiological mod-
els for transmission dynamics of two immunologically unrelated pathogens, where
immunity conferred by vaccination or natural infection of one pathogen does not
provide any cross-protection against the other pathogen. These models have the
same basic framework in the absence of vaccination, but they are structurally dif-
ferent when monovalent and bivalent vaccines are incorporated. We carried out the
theoretical analysis to show global behaviours and persistence. While the vaccine-
induced immunity wanes over time in both models, our main assumption is that
monovalent vaccines provide full protection against each pathogen, but the bivalent
vaccine provides only partial protection against both pathogens.
We compared the outcomes of vaccination in each model by means of numerical
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simulations. For this evaluation, we considered the cumulative number of infections
caused by each pathogen in the two models overtime, while changing the time du-
ration of the vaccine-induced protection. Our simulation results (Figure 1) suggest
that, within biologically feasible range of model parameters, it is possible to re-
duce the total number of infections using a bivalent vaccine with a lower number of
vaccines compared to the MVM. This is illustrated by the region between red and
dashed-black lines in Figure 1. We observed that the reduction in the total number
of infections over a certain period of time depends significantly on the duration
of the vaccine-induced protection (i.e., the parameter 1/θ). We also note that our
results are quantitatively subject to variations in the parameter space; however, we
expect that qualitative signatures of the models remain intact in epidemiologically
feasible spectra.
In models considered here, we assumed no cross-protection between the two
pathogens. When considering bivalent vaccines for different strains of the same
pathogen in the presence of cross-protection, the dynamics of disease spread and
prevention become more complex. In this case, recovery from infection with one
strain may provide partial protection against infection with another strain. Com-
plexity of disease dynamics when using this type of bivalent vaccines merits further
investigation. Additional study of the frameworks developed here for specific vac-
cines and scenarios is proceeding.
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Appendix A. Persistence and global behaviour of the MVM
Proof of Theorem 3.1. To derive the stability of the DFE, it is sufficient to
investigate the Jacobian of the infection subsystem around the DFE. The linear
system
[I ′
A
, J ′
A
, X ′
A
, I ′
B
, J ′
B
, X ′
B
]T = J · [I
A
, J
A
, X
A
, I
B
, J
B
, X
B
]T
approximates the dynamics of the infection classes in the initial phase of the epi-
demic, where J is a 6× 6 matrix, defined as
J =
[
J1 0
0 J2
]
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with J1, J2 ∈ R3×3,
J1 =

β
A
S0
N∗ − (γA + d) βA S
0
N∗ βA
S0
N∗
β
A
T 0
B
N∗ βA
T 0
B
N∗ − (γA + d) βA
T 0
B
N∗
β
A
W 0
B
N∗ βA
W 0
B
N∗ βA
W 0
B
N∗ − (γA + d)
 ,
J2 =

β
B
S0
N∗ − (γB + d) βB S
0
N∗ βB
S0
N∗
β
B
T 0
A
N∗ βB
T 0
A
N∗ − (γB + d) βB
T 0
A
N∗
β
B
W 0
A
N∗ βB
W 0
A
N∗ βB
W 0
A
N∗ − (γB + d)
 .
Let s(J) denote the maximum real part of the eigenvalues of J . For stability of
the DFE, we require s(J) < 0. It follows from the block diagonal structure of J that
the six eigenvalues of the matrix arise pairwise as the eigenvalues of the diagonal
blocks, which are
λ1 = βA
S0 + T 0
B
+W 0
B
N∗
− (γ
A
+ d), λ2 = −(γA + d), λ3 = −(γA + d),
λ4 = βB
S0 + T 0
A
+W 0
A
N∗
− (γ
B
+ d), λ5 = −(γB + d), λ6 = −(γB + d).
We note that λ2, λ3, λ5, λ6 < 0; moreover λ1 < 0 (> 0) if and only if RAm < 1
(> 1), and λ4 < 0 (> 0) if and only if RBm < 1 (> 1). These imply the local
stability of the DFE.
We define four subspaces as follows:
Υ
A
= {x ∈ Γ : I
A
= 0, J
A
= 0, X
A
= 0},
Υ
B
= {x ∈ Γ : I
B
= 0, J
B
= 0, X
B
= 0},
Ω
A
= {x ∈ Γ : I
A
+ J
A
+X
A
> 0},
Ω
B
= {x ∈ Γ : I
B
+ J
B
+X
B
> 0}.
Υ
A
and Υ
B
are the extinction spaces of pathogens A and B, respectively. Note that
Ω
A
= Γ \ Υ
A
, and Ω
A
is the subspace where pathogen A is present. Similarly, Ω
B
is the subspace where pathogen B is present, and it holds true that Ω
B
= Γ \ Υ
B
.
It is easy to see that all four subspaces are invariant with respect to model (2.3).
A.1. Behaviour in the presence of a single pathogen
We now investigate the behaviour of model (2.3) in the special case, where one of
the pathogens (say, without loss of generality, pathogen B) is absent. This confines
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the analysis to the subspace Υ
B
. For the special case where pathogen A is absent,
one can obtain similar results to those presented below.
In Υ
B
, the equations for I
B
, J
B
, and X
B
can be eliminated from model (2.3),
as I
B
= J
B
= X
B
≡ 0 implies I ′
B
= J ′
B
= X ′
B
≡ 0. We introduce new variables by
Sˆ = S + T
B
+ W
B
, Vˆ = W
A
+ W
AB
, Iˆ = I
A
+ J
A
+ X
A
, Rˆ = T
A
+ R, and obtain
the system
Sˆ′ = (1− pm(rA + rAB ))Λ− βA
Iˆ
N
Sˆ − dSˆ + θ(Vˆ + Rˆ),
Vˆ ′ = pm(rA + rAB )Λ− dVˆ − θVˆ ,
Iˆ ′ = β
A
Iˆ
N
Sˆ − γ
A
Iˆ − dIˆ,
Rˆ′ = γ
A
Iˆ − dRˆ− θRˆ,
(A.6)
where we used Sˆ+ Vˆ + Iˆ+ Rˆ = N , F
B
≡ 0, and 1−pm+pm rB = 1−pm(rA +rAB ).
With Vˆ 0 =
pm(rA+rAB )Λ
d+θ and Sˆ
0 = (1 − pm(rA + rAB ))Λd + θd Vˆ 0, the reproduction
number of system (A.6) is calculated as
β
A
(γ
A
+ d)N∗
Sˆ0 =
β
A
(γ
A
+ d)
(
1− pm(rA + rAB )d
d+ θ
)
,
and using r
A
+ r
AB
= 1− r
B
we note that this formula is the same as that of RAm
in (3.5). Hence, RAm can be used to describe the reproduction number of system
(A.6).
The system (A.6) gives a special case of the system (2) in Ref. 14. Therefore,
RAm gives the reproduction number associated with the system (2) in Ref. 14.
Following the analysis in Ref. 14, we define
Dˆ1 =
{
(Sˆ, Vˆ , Iˆ, Rˆ) ∈ R4+ : N = N∗
}
, Dˆ0 =
{
(Sˆ, Vˆ , Iˆ, Rˆ) ∈ Dˆ1 : Iˆ = 0
}
.
Theorem Appendix A.1 Consider the system (A.6). There is a unique endemic
equilibrium Eˆ1 if and only if RAm > 1. The endemic equilibrium Eˆ1 is globally
asymptotically stable in the subspace Dˆ1\Dˆ0 whenever RAm > 1. For any RAm ≥ 0
there is a unique DFE, denoted by Eˆ0, which is globally asymptotically stable in Dˆ1
whenever RAm ≤ 1.
Proof. We recall from the equation (3.1) that there is a unique equilibrium N∗ for
the total population, hence every equilibrium of (A.6) lies in Dˆ1. It follows from the
non-negativity of solutions that Dˆ1 is invariant with respect to (A.6). The dynamics
of system (A.6) restricted to Dˆ1 is equivalent to that of system (15) in Ref. 14. Using
Theorems 1, 3, and 4, and Lemmas 3 and 5 of Ref. 14, we establish the assertion of
the theorem.
It is worth mentioning that system (2) in Ref. 14 allows for the forward and
backward bifurcations at the DFE. However, the analysis of system (2) in Ref. 14
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shows that the backward bifurcation is impossible with a fully protective vaccine,
which excludes the possibility of a backward bifurcation in our system (A.6).
For system (A.6), we obtained that Sˆ, Vˆ , Iˆ, and Rˆ converge to one of the two
attractors Eˆ0 and Eˆ1. Let (Sˆ, Vˆ , Iˆ, Rˆ) → (Sˆ∗, Vˆ ∗, Iˆ∗, Rˆ∗) where (Sˆ∗, Vˆ ∗, Iˆ∗, Rˆ∗) ∈
{Eˆ0, Eˆ1}, and let F ∗A = βA Iˆ∗/N∗. We show that in model (2.3) there is a unique
equilibrium x∗ = (S∗, I∗
A
, . . . , R∗) associated with each of Eˆ0 and Eˆ1.
Theorem Appendix A.2 In model (2.3), there is a unique endemic equilibrium
EAm in ΥB if and only if RAm > 1. The equilibrium EAm is globally asymptotically
stable in the subspace Ω
A
∩ Υ
B
∩ {x ∈ Γ : N = N∗} whenever RAm > 1. For any
RAm ≥ 0, the unique DFE is globally asymptotically stable in ΥB ∩ {x ∈ Γ : N =
N∗} whenever RAm ≤ 1.
In model (2.3), there is a unique endemic equilibrium EBm in ΥA if and only if
RBm > 1. The equilibrium EBm is globally asymptotically stable in the subspace
Ω
B
∩ Υ
A
∩ {x ∈ Γ : N = N∗} whenever RBm > 1. For any RBm ≥ 0 the unique
DFE is globally asymptotically stable in Υ
A
∩{x ∈ Γ : N = N∗} whenever RBm ≤ 1.
Proof. We prove the first part of the theorem. It is obvious that T
B
→ 0, W
AB
→
W 0
AB
, andW
A
→W 0
A
in model (2.3) in the subspace Υ
B
, so let T ∗
B
= 0,W ∗
AB
= W 0
AB
,
and W ∗
A
= W 0
A
. We also note that W
B
→W ∗
B
where W ∗
B
= pmrBΛ/(d+θ+F
∗
A
) 6= 0;
thus S → S∗ where S∗ = ((1− pm)Λ + θ(Vˆ ∗+ Rˆ∗+W ∗B ))/(F ∗A + d) 6= 0. Therefore,
the components I∗
A
, J∗
A
, and X∗
A
of the equilibrium must satisfy
F ∗
A
S∗ = (γ
A
+ d)I∗
A
,
F ∗
A
T ∗
B
= (γ
A
+ d)J∗
A
,
F ∗
A
W ∗
B
= (γ
A
+ d)X∗
A
,
Iˆ∗ = I∗
A
+ J∗
A
+X∗
A
.
Note that Iˆ∗ = 0 and F ∗
A
= 0 in Eˆ0, which implies I∗A = J∗A = X∗A = 0. Furthermore,
we have Iˆ∗ > 0, F ∗
A
> 0 in Eˆ1, which implies I∗A = F ∗AS∗/(γA + d) > 0, J∗A = 0, and
X∗
A
= F ∗
A
W ∗
B
/(γ
A
+ d) > 0 (note that we used T ∗
B
= 0). In both cases, I
A
→ I∗
A
,
J
A
→ J∗
A
, and X
A
→ X∗
A
. Lastly, it is easy to see that T
A
→ T ∗
A
where T ∗
A
=
γ
A
I∗
A
/(θ + d), and R→ R∗ where R∗ = γ
A
X∗
A
/(θ + d).
In the subspace Υ
B
, the classes I
B
, J
B
, and X
B
are at zero state. Let I∗
B
=
J∗
B
= X∗
B
= 0 at any equilibrium. The equilibrium associated with Eˆ0 is a DFE of
model (2.3), and by uniqueness, it follows that it is the DFE given in (3.3). At the
equilibrium of the model (2.3) that is associated with Eˆ1, we have I∗A , X∗A > 0. We
denote this equilibrium by EAm, which is an endemic equilibrium with respect to
pathogen A and disease-free equilibrium with respect to pathogen B. We refer to
EAm as the boundary endemic equilibrium of model (2.3) in the presence of pathogen
A and in the absence of pathogen B.
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A.2. Persistence and global behavior
We recall from the equation (3.1) that the total population converges to the equi-
librium N∗. We consider model (2.3) as a non-autonomous system with nonau-
tonomous term N(t), which is governed by (3.1). By limt→∞N(t) = N∗, model
(2.3) is asymptotically autonomous with the limiting system which arises from (2.3)
by replacing N(t) with N∗. In this section our analysis is restricted to the case when
the total population is at its steady state, that is, N = N∗. By the theory of asymp-
totically autonomous systems (see Refs. 15–17) the dynamics of the limiting system
is qualitatively equivalent to that of the original model (2.3).
Note that the equation for W
AB
in model (2.3) is independent from other
equations, and limt→∞WAB = W
0
AB
= (pm rAB )Λ/(d + θ). This means that
limt→∞(N −WAB ) = Λ/d− (pm rAB )Λ/(d+ θ). We define the quantities
RcAm =
β
A
(γ
A
+ d)
(
1− d pm rAB
d+ θ
)
,
RcBm =
β
B
(γ
B
+ d)
(
1− d pm rAB
d+ θ
)
.
Note that RAm ≤ RcAm and RBm ≤ RcBm.
Theorem Appendix A.3 In the subspace ΓW = {x ∈ Γ : W
AB
≥ (pm rAB )Λ/(d+
θ)} each solution converges to the subspace Υ
A
∩ ΓW (to the subspace Υ
B
∩ ΓW ) if
RcAm ≤ 1 (RcBm ≤ 1).
Proof. Suppose RcAm ≤ 1, and consider the Lyapunov function V1(x) = IA +JA +
X
A
. The derivative of V1 along the solutions of the system is
V˙1 = (IA + JA +XA)(γA + d)
(
β
A
(γ
A
+ d)N∗
(S + T
B
+W
B
)− 1
)
.
In the subspace ΓW , we have S + T
B
+W
B
≤ N∗ − (p r
AB
)Λ/(d+ θ), hence
V˙1 ≤(IA + JA +XA)(γA + d)
(
β
A
(γ
A
+ d)N∗
(
N∗ − (pm rAB )Λ
d+ θ
)
− 1
)
.
The derivative V˙1 ≤ 0 if RcAm ≤ 1. Note that V˙1 = 0 if and only if IA+JA+XA =
0 or S+T
B
+W
B
= N∗− (pm rAB )Λ/(d+ θ), although the latter is only possible if
I
A
= J
A
= X
A
= 0. Thus, the subspace where V˙1 = 0 is ΥA . It follows from LaSalle’s
invariance principle that limt→∞(IA+JA+XA) = 0 holds for each solution, implying
that pathogen A dies out. One can show similarly the result for pathogen B by using
the Lyapunov function V2(x) = IB + JB +XB .
Theorem Appendix A.4 The DFE is globally asymptotically stable in the sub-
space ΓW = {x ∈ Γ : W
AB
≥ (p r
AB
)Λ/(d+ θ)} if RcAm ≤ 1 and RBm ≤ 1, or if
RcBm ≤ 1 and RAm ≤ 1.
Proof. Suppose RcAm ≤ 1 and RBm ≤ 1, and consider the Lyapunov function
V1 as defined in the previous theorem. Therefore V˙1 ≤ 0, and the largest invariant
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set in V1 = 0 is the DFE. Thus, by Theorem Appendix A.1, the DFE is globally
asymptotically stable in Υ
A
.
Similarly, when RcBm ≤ 1 and RAm ≤ 1, we obtain for V2(x) = IB + JB +XB
that V˙2 ≤ 0. Moreover the largest invariant set in V2 = 0 is the DFE. Thus, in both
cases, the limit set of each solution is the DFE, which proves the theorem.
Theorem Appendix A.5 In the subspace ΓW ∩ Ω
B
, EBm is globally asymptoti-
cally stable if RcAm ≤ 1 and RBm > 1. In the subspace ΓW ∩ ΩA , EAm is globally
asymptotically stable if RcBm ≤ 1 and RAm > 1.
Proof. Suppose RcAm ≤ 1 and RBm > 1, and consider the Lyapunov function
V1 as defined above. It can be shown that V˙1 ≤ 0, and the largest invariant set in
V1 = 0 is E
B
m; thus by Theorem Appendix A.1, the DFE is globally asymptotically
stable in Υ
A
∩ Ω
B
.
Similarly, when RcBm ≤ 1 and RAm > 1 we obtain for V2(x) = IB + JB + XB
that V˙2 ≤ 0. Moreover the largest invariant set in V2 = 0 is the EAm. Hence, the
results follow from LaSalle’s invariance principle.
We continue our analysis with investigating persistence in model (2.3). We in-
troduce two new quantities. Let R∗Am be the expected number of new infections
with pathogen A when an individual infected with pathogen A is introduced into
the population that is at the steady state EBm. Let R∗Bm be the expected number
of new infections with pathogen B when an individual infected with pathogen B is
introduced into the population that is at the steady state EAm. The expressions for
R∗Am and R∗Bm read
R∗Am =
β
A
N∗(γ
A
+ d)
(S∗ + T ∗
B
+W ∗
B
),
R∗Bm =
β
A
N∗(γ
A
+ d)
(S∗ + T ∗
A
+W ∗
A
),
where S∗, T ∗
B
, and W ∗
B
are the states of the corresponding classes at the equilib-
rium EBm, and S
∗, T ∗
A
, and W ∗
A
are the states of the corresponding classes at the
equilibrium EAm.
Lemma Appendix A.1 In model (2.3), R∗Am < RAm and R∗Bm < RBm.
Proof. We show that S∗ + T ∗
A
+ W ∗
A
< S0 + W 0
A
, where S∗, T ∗
A
, and W ∗
A
are the
states of the corresponding classes at the equilibrium EAm, and S
0 and W 0
A
are the
states of the corresponding classes at the DFE. Hence R∗Bm < RBm.
Recall that the pathogen B is absent at both the DFE and EAm. Therefore W
0
A
=
W ∗
A
and W 0
AB
= W ∗
AB
. Furthermore, at any equilibrium, the total population is at
the steady state N∗, and we obtain
S0 +W 0
B
= S∗ + T ∗
A
+W ∗
B
+ I∗
A
+X∗
A
+R∗.
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Equating the right hand sides of the equations in model (2.3) to zero, it is easy
to see that T ∗
A
= γ
A
I∗
A
/(θ + d) and R∗ = γ
A
X∗
A
/(θ + d); thus we derive from the
above equation that
S0 +W 0
B
= S∗ +W ∗
B
+ (I∗
A
+X∗
A
)
(
1 +
γ
A
θ + d
)
W 0
B
−W ∗
B
− (I∗
A
+X∗
A
)− γA
θ + d
X∗
A
= S∗ + T ∗
A
− S0.
Since W 0
B
= pm rBΛ(d+ θ) and (d+ θ)W
∗
B
= pm rBΛ− βA(I∗A +X∗A)W ∗B/N∗, from
the ninth equation of (2.3), we obtain
(W 0
B
−W ∗
B
− (I∗
A
+X∗
A
)− γA
θ + d
X∗
A
)(d+ θ)
= (I∗
A
+X∗
A
)
(
β
A
N∗
W ∗
B
− (d+ θ)
)
− γ
A
X∗
A
= −I∗
A
(d+ θ)− γ
A
X∗
A
< 0,
where for the last equality we used (I∗
A
+ X∗
A
)β
A
W ∗
B
/N∗ − X∗
A
(d + θ) = 0 from
the tenth equilibrium equation of (2.3). Hence S∗ + T ∗
A
< S0, which implies S∗ +
T ∗
A
+W ∗
A
< S0 +W 0
A
and R∗Bm < RBm. The relation R∗Am < RAm can be proven
similarly.
We now recall some definitions and results from Ref. 18.
Definition Appendix A.1 Let X be an arbitrary nonempty set and ρ : X → R+.
A semiflow Φ : R+ × X → X is called uniformly weakly ρ-persistent, if there
exists some  > 0 such that
lim sup
t→∞
ρ(Φ(t, x)) >  ∀x ∈ X, ρ(x) > 0.
Φ is called uniformly (strongly) ρ-persistent, if there exists some  > 0 such that
lim inf
t→∞ ρ(Φ(t, x)) >  ∀x ∈ X, ρ(x) > 0.
A set M in X is called uniformly weakly ρ-repelling if there is no x ∈ X such that
ρ(x) > 0 and Φ(t, x)→M as t→∞.
Uniformly weakly ρ-persistence is a property that is weaker than uniformly
(strongly) ρ-persistence. However, Theorem 4.5 in Ref. 18 establishes conditions
on X and Φ such that uniformly weakly ρ-persistence implies uniformly (strongly)
ρ-persistence.
In what follows, we present uniformly persistence results for model (2.3). It is
easy to see that the model generates a continuous flow on the phase space. After
showing weakly persistence for some choices of ρ, we will consider the conditions
of Theorem 4.5 in Ref. 18 to prove uniformly (strongly) persistence. We will also
use Theorem 8.17 in Ref. 18 to assert uniformly weakly ρ-persistence, by examining
some uniformly weakly ρ-repelling sets.
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The ω-limit set of a point x ∈ X is defined as
ω(x) = {y ∈ X : ∃{tn}n≥1 such that tn →∞,Φ(tn, x)→ y as n→∞} .
Theorem Appendix A.6 I
A
+J
A
+X
A
is uniformly (strongly) persistent in Ω
A
if
either R∗Am > 1, or RAm > 1 and RBm ≤ 1. IB +JB +XB is uniformly (strongly)
persistent in Ω
B
if either R∗Bm > 1, or RBm > 1 and RAm ≤ 1.
Proof. We prove the theorem for the persistence of pathogen A only. The phase
space Γ is nonempty, so let X = Γ and x = (S, I
A
, . . . , R) ∈ Γ be any state of the
model. Consider ρ(x) = I
A
+ J
A
+X
A
. Then we have
{x ∈ Γ: ρ(x) = 0} = Υ
A
,
the extinction space of pathogen A. We investigate Ω := ∪x∈Υ
A
ω(x). From Theorem
Appendix A.2, it follows that Ω = M1 ∪M2 whenever RBm > 1, and Ω = M1
whenever RBm ≤ 1, where M1 is the DFE and M2 = EBm.
First, we show that M1 is uniformly weakly ρ-repelling if RAm > 1. Suppose
there is some x such that ρ(x) > 0 and Φ(t, x)→ M1 as t→∞; that is, there is a
solution such that I
A
(t)+J
A
(t)+X
A
(t) > 0 but limt→∞(IA(t)+JA(t)+XA(t)) = 0
and limt→∞(S(t) + WB (t) + TB (t)) = S
0 + W 0
B
+ T 0
B
. Thus, for any  > 0 and
sufficiently large t > 0, we have S(t) +W
B
(t) + T
B
(t) > S0 +W 0
B
+ T 0
B
− . For the
derivative of I
A
+ J
A
+X
A
, we obtain
(I
A
+ J
A
+X
A
)′ = (I
A
+ J
A
+X
A
) (β
A
(S + T
B
+W
B
)− (γ
A
+ d))
> (γ
A
+ d)(I
A
+ J
A
+X
A
)
(
β
A
γ
A
+ d
(S0 +W 0
B
+ T 0
B
− )− 1
)
= (γ
A
+ d)(I
A
+ J
A
+X
A
)
(
RAm −  βA
γ
A
+ d
− 1
)
,
which is positive for small  by RAm > 1, contradicting limt→∞(IA(t) + JA(t) +
X
A
(t)) = 0. Note that this result holds when R∗Am > 1, as R∗Am > 1 implies
RAm > 1.
We derive similarly that M2 is uniformly weakly ρ-repelling if R∗Am > 1.
Assume the contrary, there is a solution such that I
A
(t) + J
A
(t) + X
A
(t) > 0
but limt→∞(IA(t) + JA(t) + XA(t)) = 0 and limt→∞(S(t) + WB (t) + TB (t)) =
S∗ + W ∗
B
+ T ∗
B
, where S∗, W ∗
B
, and T ∗
B
are the corresponding components of EBm.
For any  > 0 and sufficiently large t > 0, we derive
(I
A
+ J
A
+X
A
)′ = (I
A
+ J
A
+X
A
) (β
A
(S + T
B
+W
B
)− (γ
A
+ d))
> (γ
A
+ d)(I
A
+ J
A
+X
A
)
(
β
A
γ
A
+ d
(S∗ +W ∗
B
+ T ∗
B
− )− 1
)
= (γ
A
+ d)(I
A
+ J
A
+X
A
)
(
R∗Am − 
β
A
γ
A
+ d
− 1
)
> 0,
where we used S(t)+W
B
(t)+T
B
(t) > S∗+W ∗
B
+T ∗
B
−. However, (I
A
+J
A
+X
A
)′ > 0,
which contradicts limt→∞(IA(t) + JA(t) +XA(t)) = 0.
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Suppose now RBm ≤ 1 and RAm > 1. Then Ω ⊂M1, M1 is isolated, compact,
invariant, acyclic, and weakly ρ-repelling. Therefore, Theorem 8.17 in Ref. 18 implies
that I
A
+ J
A
+X
A
is weakly ρ-persistent. However, we recall again that R∗Am > 1
implies RAm > 1, hence the last statement also holds when RBm ≤ 1 and R∗Am >
1. If RBm > 1, then Ω ⊂ (M1 ∪M2), M1 and M2 are invariant, isolated, compact,
and weakly ρ-repelling if R∗Am > 1, and {M1,M2} is acyclic. Thus, by Theorem
8.17 in Ref. 18, we conclude that I
A
+ J
A
+X
A
is weakly ρ-persistent if R∗Am > 1
and RBm > 1.
It remains to show that weakly ρ-persistence implies uniformly (strong) ρ-
persistence. The phase space X is compact, hence there exists a compact attractor.
Moreover our flow is continuous, and therefore we can apply Theorem 4.5 in Ref. 18
to assert uniformly (strongly) persistence.
The question of whether I
A
+ J
A
+ X
A
is uniformly persistent in Ω
A
when
R∗Am ≤ 1 < RAm and RBm > 1 remains unaddressed. However, based on numeri-
cal experiments, we conjecture that this assertion holds true. If so, this result, to-
gether with Theorem Appendix A.6 means that I
A
+J
A
+X
A
is uniformly persistent
in Ω
A
when RAm > 1. Similar conjecture is proposed for the uniform persistence
of I
B
+ J
B
+X
B
in Ω
B
when RBm > 1.
Theorem Appendix A.7 In the subspace Ω
A
∩Ω
B
, I
A
+J
A
+X
A
+I
B
+J
B
+X
B
is uniformly (strongly) persistent if min{RAm, RBm} > 1.
Proof. For X = Γ and x = (S, I
A
, . . . , R) ∈ Γ, we consider ρ(x) = I
A
+ J
A
+X
A
+
I
B
+ J
B
+X
B
. Then, the disease-free subspace is
{x ∈ Γ: ρ(x) = 0} = {(S, I
A
, . . . , R) : I
A
= J
A
= X
A
= I
B
= J
B
= X
B
= 0} .
In the absence of both pathogens, the system is linear and the DFE is globally
asymptotically stable. Let Ω := M1 where M1 is the DFE. We show that M1 is
uniformly weakly ρ-repelling if RAm > 1 and RBm > 1. Suppose there exists a
solution such that I
A
(t) + J
A
(t) + X
A
(t) > 0 and I
B
(t) + J
B
(t) + X
B
(t) > 0 but
limt→∞(IA(t)+JA(t)+XA(t)+IB (t)+JB (t)+XB (t)) = 0 and limt→∞(S(t)+WB (t)+
T
B
(t)) = S0 + W 0
B
+ T 0
B
. Then, for any  > 0 and sufficiently large t > 0, we have
S(t)+W
B
(t)+T
B
(t) > S0+W 0
B
+T 0
B
− and S(t)+W
A
(t)+T
A
(t) > S0+W 0
A
+T 0
A
−.
We obtain
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(I
A
+ J
A
+X
A
+ I
B
+ J
B
+X
B
)′
= (I
A
+ J
A
+X
A
) (β
A
(S + T
B
+W
B
)− (γ
A
+ d))
+ (I
B
+ J
B
+X
B
) (β
B
(S + T
A
+W
A
)− (γ
B
+ d))
> (γ
A
+ d)(I
A
+ J
A
+X
A
)
(
β
A
γ
A
+ d
(S0 +W 0
B
+ T 0
B
− )− 1
)
+ (γ
B
+ d)(I
B
+ J
B
+X
B
)
(
β
B
γ
B
+ d
(S0 +W 0
A
+ T 0
A
− )− 1
)
= (γ
A
+ d)(I
A
+ J
A
+X
A
)
(
RAm −  βA
γ
A
+ d
− 1
)
+ (γ
B
+ d)(I
B
+ J
B
+X
B
)
(
RBm −  βB
γ
B
+ d
− 1
)
,
which is positive for small  since RAm > 1 and RBm > 1, contradicting
limt→∞(IA(t) + JA(t) +XA(t) + IB (t) + JB (t) +XB (t)) = 0.
We apply Theorem 8.17 in Ref. 18 to derive that I
A
+X
A
+ I
B
+X
B
is weakly
ρ-persistent. We note that Ω ⊂ M1, M1 is isolated, compact, invariant, acyclic,
and weakly ρ-repelling. The phase space X is compact, and hence there exists a
compact attractor. Furthermore, the flow is continuous, and thus Theorem 4.5 in
Ref. 18 implies uniformly (strongly) persistence.
The above theorem can be extended by noting that I
A
+ J
A
+ X
A
persists if
RAm > 1 and RBm ≤ 1, and IB + JB +XB persists if RBm > 1 and RAm ≤ 1.
Corollary Appendix A.1 In the subspace Ω
A
∩Ω
B
, I
A
+J
A
+X
A
+I
B
+J
B
+X
B
is uniformly (strongly) persistent if max{RAm, RBm} > 1.
Appendix B. Persistence and global behaviour of the BVM
B.1. Behavior in the presence of a single pathogen
Similar to model (2.3) (the MVM), we define Υ
A
and Υ
B
in the BVM as the
extinction spaces of pathogens A and B, respectively, and Ω
A
(Ω
B
) as the subspace
where only pathogen A (only pathogen B) is present:
Υ
A
= {x ∈ Γ : I
A
= 0, J
A
= 0, X
A
= 0, Y
A
= 0},
Υ
B
= {x ∈ Γ : I
B
= 0, J
B
= 0, X
B
= 0, Y
B
= 0},
Ω
A
= {x ∈ Γ : I
A
+ J
A
+X
A
+ Y
A
> 0},
Ω
B
= {x ∈ Γ : I
B
+ J
B
+X
B
+ Y
B
> 0}.
It is easy to see that all four subspaces are invariant with respect to model (2.5).
We investigate the model (2.5) in the special case where one of the pathogens
(say, without loss of generality, pathogen B) is absent. The analysis in this subsection
is therefore restricted to the subspace Υ
B
. For the special case where pathogen A
is absent, one can obtain similar results to those presented here.
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In the subspace Υ
B
, the equations for I
B
, J
B
, X
B
, and Y
B
can be eliminated
from model (2.5), as I
B
= J
B
= X
B
= Y
B
≡ 0 implies I ′
B
= J ′
B
= X ′
B
= Y ′
B
≡ 0.
We introduce new variables: S˘ = S + T
B
, V˘ = V
AB
+Q
B
, I˘ = I
A
+ J
A
+X
A
+ Y
A
,
R˘ = T
A
+Q
A
+R, and obtain the following system
S˘′ = (1− pb)Λ− βA
I˘
N
S˘ − dS˘ + θ(V˘ + R˘),
V˘ ′ = pb Λ− κAβA
I˘
N
V˘ − dV˘ − θV˘ ,
I˘ ′ = β
A
I˘
N
S˘ + κ
A
β
A
I˘
N
V˘ − γ
A
I˘ − dI˘,
R˘′ = γ
A
I˘ − dR˘− θR˘,
(B.2)
where we used S˘ + V˘ + I˘ + R˘ = N and F
B
≡ 0. With V˘ 0 = pbΛd+θ and S˘0 =
(1− pb)Λd + θd V˘ 0, the reproduction number of (B.2) is calculated as
β
A
(γ
A
+ d)N∗
(S˘0 + κ
A
V˘ 0) =
β
A
(γ
A
+ d)
(
1− pb(1− κA)d
d+ θ
)
,
and we note that this formula is the same as that of RAb in (4.3). Hence, RAb can
be used to describe the reproduction number of system (B.2).
The system (B.2) gives a special case of system (2) in Ref. 14. Thus, RAb
gives the reproduction number associated with system (2) in Ref. 14. Following the
analysis of Ref. 14, we define
D˘1 =
{
(S˘, V˘ , I˘, R˘) ∈ R4+ : N = N∗
}
,
D˘0 =
{
(S˘, V˘ , I˘, R˘) ∈ D˘1 : I˘ = 0
}
.
The following results are obtained by similar arguments as those in Theorem Ap-
pendix A.1.
Theorem Appendix B.1 Consider system (B.2). There is a unique endemic
equilibrium E˘1 if and only if RAb > 1. The endemic equilibrium E˘1 is globally
asymptotically stable in the subspace D˘1 \D˘0 whenever RAb > 1. For any RAb > 0,
there is a unique DFE E˘0, that is globally asymptotically stable in D˘1 whenever
RAb ≤ 1.
We obtained that S˘, V˘ , I˘, and R˘ converge in system (B.2). Let (S˘, V˘ , I˘, R˘) →
(S˘∗, V˘ ∗, I˘∗, R˘∗) where (S˘∗, V˘ ∗, I˘∗, R˘∗) ∈ {E˘0, E˘1}, and let F ∗A = βA I˘∗/N∗. We show
that in model (2.5) there is a unique equilibrium x∗ = (S∗, I∗
A
, . . . , R∗) ∈ R15
associated with each of E˘0 and E˘1.
Theorem Appendix B.2 In model (2.5), there is a unique endemic equilibrium
EAb in ΥB if and only if RAb > 1. The equilibrium EAb is globally asymptotically
stable in the subspace Ω
A
∩ Υ
B
∩ {x ∈ Γ : N = N∗} whenever RAb > 1. For any
RAb ≥ 0, the unique DFE is globally asymptotically stable in ΥB∩{x ∈ Γ : N = N∗}
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whenever RAb ≤ 1.
In model (2.5), there is a unique endemic equilibrium EBb in ΥA if and only if
RBb > 1. The equilibrium EBb is globally asymptotically stable in the subspace ΩB ∩
Υ
A
∩ {x ∈ Γ : N = N∗} whenever RBb > 1. For any RBb ≥ 0, the unique DFE is
globally asymptotically stable in Υ
A
∩ {x ∈ Γ : N = N∗} whenever RBb ≤ 1.
Proof. Indeed, it is obvious that T
B
→ 0 and Q
B
→ 0 in the subspace Υ
B
. Let
T ∗
B
= 0 and Q∗
B
= 0. Then S → S˘∗ and V
AB
→ V˘ ∗
AB
, and we let S∗ = S˘∗ and
V ∗
AB
= V˘ ∗
AB
. It follows from model (2.5) that the components I∗
A
, J∗
A
, X∗
A
and Y ∗
A
of
the equilibrium need to satisfy
F ∗
A
S∗ = (γ
A
+ d)I∗
A
,
F ∗
A
T ∗
B
= (γ
A
+ d)J∗
A
,
κ
A
F ∗
A
V ∗
AB
= (γ
A
+ d)X∗
A
,
F ∗
A
Q∗
B
= (γ
A
+ d)Y ∗
A
,
I∗
A
+ J∗
A
+X∗
A
+ Y ∗
A
= I˘∗.
However, T
B
→ 0 and Q
B
→ 0 imply that J
A
→ J∗
A
and Y
A
→ Y ∗
A
with J∗
A
=
Y ∗
A
= 0. Note that I˘∗ = 0 and F ∗
A
= 0 at E˘0, which implies I∗A = X∗A = 0. On
the other hand, we have I˘∗ > 0, F ∗
A
> 0 at E˘1; hence I∗A = F ∗AS∗/(γA + d) > 0
and X∗
A
= F ∗
A
V ∗
AB
/(γ
A
+ d) > 0. In both cases, I
A
→ I∗
A
and X
A
→ X∗
A
. Finally,
it is easy to see that T
A
→ T ∗
A
and Q
A
→ Q∗
A
where T ∗
A
= (γ
A
I∗
A
)/(θ + d) and
Q∗
A
= (γ
A
X∗
A
)/(θ + d) and moreover R→ 0, giving R∗ = 0.
Note that in the subspace Υ
B
, the classes I
B
, J
B
, X
B
, and Y
B
are at zero state;
thus I∗
B
= J∗
B
= X∗
B
= Y ∗
B
= 0 at any equilibrium in Υ
B
. The equilibrium associated
with E˘0 is therefore a disease-free equilibrium in model (2.5), and by uniqueness it
follows that it is the DFE. At the equilibrium of model (2.5) that is associated
with E˘1, it follows that I∗A , X∗A > 0. We denote this equilibrium by EAb , which is an
endemic equilibrium with respect to pathogen A and disease-free with respect to
pathogen B. We refer to EAb as the boundary endemic equilibrium of model (2.5)
in the presence of pathogen A and in the absence of pathogen B. With the above
arguments, we have proven the first part of the theorem, and the second part can
be shown similarly.
B.2. Persistence
Here, we show sufficient conditions for the persistence of the disease in model (2.5).
We again define the reproduction number R∗Ab (R∗Bb), when the population is at
its steady state EBb (E
A
b ). The expressions for R∗Ab and R∗Bb read
R∗Ab =
β
A
(γ
A
+ d)N∗
(S∗ + T ∗
B
+ κ
A
(V ∗
AB
+Q∗
B
)),
R∗Bb =
β
B
(γ
B
+ d)N∗
(S∗ + T ∗
A
+ κ
B
(V ∗
AB
+Q∗
A
)),
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where S∗, T ∗
B
, V ∗
AB
, and Q∗
B
are the states of the corresponding classes at the
equilibrium EBb , and S
∗, T ∗
A
, V ∗
AB
, and Q∗
A
are the states of the corresponding
classes at the equilibrium EAb .
Lemma Appendix B.1 In model (2.5), R∗Ab < RAb and R∗Bb < RBb.
Proof. We show that S∗ + T ∗
A
+ κ
B
(V ∗
AB
+ Q∗
A
) < S0 + κ
B
V 0
AB
, where S0 and
V 0
AB
are the states of the corresponding classes at the DFE. Then, it follows that
R∗Bb < RBb.
Recall that pathogen B is absent at both equilibria. Equating the right hand
sides of the equations for Q
A
, V
AB
, and X
A
in model (2.5) to zero, we obtain
κ
A
F ∗
A
V ∗
AB
= (γ
A
+ d)X∗
A
,
V ∗
AB
=
pbΛ
d+ θ
− κAF
∗
A
V ∗
AB
d+ θ
=
pbΛ
d+ θ
− (γA + d)X
∗
A
d+ θ
,
V 0
AB
=
pbΛ
d+ θ
,
Q∗
A
=
γ
A
X∗
A
d+ θ
.
Using these equalities, we derive
V 0
AB
− V ∗
AB
−Q∗
A
=
pbΛ
d+ θ
−
(
pbΛ
d+ θ
− (γA + d)X
∗
A
d+ θ
)
− γAX
∗
A
d+ θ
=
dX∗
A
d+ θ
.
Since the total population is at the steady state N∗ at any equilibrium, we obtain
S∗ + I∗
A
+ T ∗
A
+ V ∗
AB
+X∗
A
+Q∗
A
= S0 + V 0
AB
,
which we use to express S∗ + T ∗
A
− S0, as
S∗ + T ∗
A
− S0 = V 0
AB
− I∗
A
− V ∗
AB
−X∗
A
−Q∗
A
= −I∗
A
− θX
∗
A
d+ θ
.
Since dX∗
A
/(d+ θ) > 0 and −I∗
A
− θX∗
A
(d+ θ) < 0, it follows from κ
B
≥ 0 that
−I∗
A
− θX
∗
A
d+ θ
< κ
B
dX∗
A
d+ θ
,
S∗ + T ∗
A
− S0 < κ
B
(V 0
AB
− V ∗
AB
−Q∗
A
),
S∗ + T ∗
A
+ κ
B
(V ∗
AB
+Q∗
A
) < S0 + κ
B
V 0
AB
,
which yields R∗Bb < RBb. The other inequality R∗Ab < RAb can be proven using a
similar argument.
The results for persistence are obtained by applying analogous arguments to
those in Theorems Appendix A.6 and Appendix A.7. For the proofs, one may con-
sider the functions ρ = I
A
+J
A
+X
A
+Y
A
and ρ = I
A
+J
A
+X
A
+Y
A
+ I
B
+J
B
+
X
B
+ Y
B
. Without detailing their proofs, we state the following results for model
(2.5).
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Theorem Appendix B.3 I
A
+J
A
+X
A
+Y
A
is uniformly (strongly) persistent in
Ω
A
if either R∗Ab > 1, or RAb > 1 and RBb ≤ 1. IB + JB +XB + YB is uniformly
(strongly) persistent in Ω
B
if either R∗Bb > 1, or RBb > 1 and RAb ≤ 1.
Theorem Appendix B.4 In the subspace Ω
A
∩ Ω
B
, I
A
+ J
A
+ X
A
+ Y
A
+ I
B
+
J
B
+ X
B
+ Y
B
is uniformly (strongly) persistent if min{RAb, RBb} > 1 (if
max{RAb, RBb} > 1).
